{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiglbvrd7gdyiff3ebdhhutc3vde6hjb3gt4efngs2vpmqx3z35dyi",
    "uri": "at://did:plc:svcthvzunxmjidtlw23zva6n/app.bsky.feed.post/3mmur4pnsyaq2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihl7g4wczznhygy3no7hd3dxuntnphlzfi72pvsbp6z4k4zl2ml4q"
    },
    "mimeType": "image/jpeg",
    "size": 10257
  },
  "path": "/2026/05/27/dizals-zegfrovy-sunvozertinib-new-drug-application-accepted-and-granted-priority-review-by-china-national-medical-products-administration-for-first-line-treatment-of-egfr-exon-20-insertion-mu/",
  "publishedAt": "2026-05-27T10:40:00.000Z",
  "site": "https://laotiantimes.com",
  "tags": [
    "Cision PR Newswire"
  ],
  "textContent": "SHANGHAI, May 27, 2026 /PRNewswire/ — Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of oncology and hematological diseases, announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted and granted priority review to the New Drug Application (NDA) for ZEGFROVY® (sunvozertinib) for […]",
  "title": "Dizal’s ZEGFROVY® (Sunvozertinib) New Drug Application Accepted and Granted Priority Review by China National Medical Products Administration for First-Line Treatment of EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer"
}